In a high-dose immediate-release tablet train, Apotel paracetamol API is rarely compressed as the sole powder because the unmodified crystal exhibits low compactibility and a measurable tendency to cap or laminate at main compression forces exceeding the range typical for starch-based or microcrystalline cellulose diluent systems. For a 500 mg core, the preferred production route is dry granulation by roller compaction, with the API fraction held at 85–90% w/w, pregelatinised starch or low-moisture microcrystalline cellulose at 5–10% w/w, crospovidone or sodium starch glycolate at 2–4% w/w, and magnesium stearate at 0.5–1.0% w/w. Ribbon density is controlled between 1.05 g/cm³ and 1.30 g/cm³ before milling through a 0.8 mm screen, because lower ribbon density regenerates fines and higher ribbon density work-hardens the API surface. Compression on a rotary press with precompression stations uses precompression forces of 4–8 kN and main compression forces of 15–25 kN, producing tablet hardness from 60 N to 100 N and friability not more than 0.8% after 100 revolutions using USP Chapter <1216> methodology. The release test is driven by USP Chapter <711> apparatus 2 at 50 rpm in 900 mL of pH 5.8 phosphate buffer, with a typical immediate-release acceptance criterion of not less than 80% dissolved in 30 min. Disintegration is evaluated according to USP Chapter <701> with a limit of not more than 15 min in water at 37°C. Blend uniformity is confirmed under USP Chapter <905> with acceptance value L1 not more than 15.0, and moisture ingress during storage must be prevented because granules exposed to relative humidity above 60% show increased capping frequency and delayed dissolution due to stearate redistribution. Batch records for production-scale compaction commonly specify final granule loss on drying below 1.5% before lubrication, since residual moisture above this value can reduce tablet tensile strength even when hardness remains within the target window.

What Limits Fill Weight Uniformity in Paracetamol Capsule Filling?

The fill weight variability of hard gelatin capsules containing paracetamol is governed less by the chemical purity of the API and more by the flow state of the granulate after binder addition and drying. Unmilled paracetamol powder typically has poor flow and high interparticle friction, so capsule formulations are wet-granulated rather than directly filled. A standard capsule granulate contains 80–88% w/w paracetamol, 8–12% w/w lactose monohydrate or mannitol, 2.5–5.0% w/w povidone K30 as binder, and 2–4% w/w crospovidone as disintegrant. The granulating fluid is purified water added to a high-shear mixer at 18–25% w/w of dry powder mass, with impeller speed set between 300 rpm and 500 rpm and chopper speed between 1500 rpm and 3000 rpm. Wet mass is passed through a 4.0 mm screen and dried in a fluid-bed dryer with inlet air at 60–70°C until product temperature stabilises at 35–45°C; the target loss on drying is 1.0–2.0%. Dry granules are milled through a 0.8 mm or 1.0 mm screen, and the resulting particle-size distribution is maintained with not more than 20% fines below 150 µm. Tamping-pin or dosator capsule machines fill size 0 or size 00 hard gelatin shells to a target fill weight of 450–550 mg, and fill weight relative standard deviation is held below 2.0% at steady state. Capsule weight variation is checked under USP Chapter <905>, and the dissolution method mirrors the tablet method using USP Chapter <711> apparatus 2 at 50 rpm with 900 mL of pH 5.8 phosphate buffer. A specific packaging concern is moisture migration between the fill and the gelatin shell; storage at 40–50% relative humidity prevents shell embrittlement and keeps shell water content in the 13–16% range described in gelatin capsule technical literature. The process is less thermally sensitive than injection manufacture, but hygroscopic diluents such as maize starch can shift moisture into the granulate and reduce brittleness of the API during compression or filling.

A sachet granulate for oral suspension is formulated around the limited aqueous solubility of paracetamol, approximately 14.3 mg/mL at 25°C, so complete dissolution is not the rate-limiting requirement; rapid dispersion and uniform dose delivery from the reconstituted suspension are the controlling powder properties. A single-dose sachet for paediatric or geriatric use typically delivers 125 mg or 250 mg paracetamol in a 1–2 g powder mass, with the API fraction at 10–25% w/w because the bulk is composed of sucrose, mannitol, sorbitol, or maltodextrin. Wet granulation is performed in a high-shear mixer using povidone K30 or pregelatinised starch as binder at 2–5% w/w, with granulating fluid at 15–20% w/w. Drying in a fluid-bed processor at inlet air 55–65°C is terminated at loss on drying 0.8–1.5%, followed by size classification to retain granules between 150 µm and 710 µm with fines below 10%. Xanthan gum or microcrystalline cellulose is added at 0.2–0.5% w/w to impart suspending properties after reconstitution in water, and sodium starch glycolate is used at 2–4% w/w to support rapid wetting. The reconstituted suspension is assessed for sedimentation volume and pourability, and the sachet fill weight is controlled under the same pharmacopoeial uniformity framework as other solid dosage forms. Because the API is present as suspended particles, the finished product monograph may require a dissolution test rather than a simple clarity test, with the apparatus and medium defined by the specific regulatory dossier. Packaging in aluminium foil laminate sachets with moisture vapour transmission below 0.1 g/m²/day is used to maintain granule friability and prevent caking during distribution in hot and humid climates.

Effervescent Granulation Stoichiometry and Moisture Control

The effervescent paracetamol granulate is a moisture-intolerant system in which the acid–base couple is selected to achieve rapid disintegration and a buffered aqueous environment for API dispersion. For a formulation using anhydrous citric acid and sodium bicarbonate, the stoichiometric acid-to-base mass ratio is approximately 1:1.31 because one mole of citric acid reacts with three moles of sodium bicarbonate; commercial formulations often adjust this ratio to 1:1.0 or 1:1.2 to maintain a slight acid excess and pleasant mouthfeel. The API content ranges from 15–30% w/w in a 2–4 g sachet or tablet, with sodium content becoming a label-critical parameter because a single dose can contribute more than 400 mg of sodium. Processing is conducted in rooms maintained at or below 25% relative humidity and 22°C, and excipient moisture is checked before blending; total loss on drying above 0.5% initiates the acid–base reaction prematurely and causes granule swelling, punch sticking, and carbon dioxide loss during storage. Direct compression is preferred over aqueous granulation, with the granulate prepared by dry blending the API, acid, bicarbonate, sweetener, and flavour, followed by lubrication with polyethylene glycol 6000 at 2–4% w/w because magnesium stearate can form insoluble soaps in effervescent solutions. Tablet hardness is kept between 30 N and 60 N, with disintegration tested in 200 mL of water at 25°C; a typical upper limit is 5 min. The robust production-scale failure mode is not chemical instability of the API but granule pre-reaction due to insufficient environmental control, leading to loss of effervescent power and increased friability during bulk storage. Therefore, the granulate is packed immediately into aluminium strip packs or desiccant-containing foil sachets with an oxygen barrier layer, and the residual moisture of the sealed primary pack is verified before release.

When Co-Solvent Oral Syrup Systems Are Used for Paediatric Paracetamol Delivery

Liquid oral formulations require a co-solvent strategy because the target strength of 250 mg/5 mL or 120 mg/5 mL exceeds the aqueous solubility of paracetamol at room temperature, and the solution must remain physically stable across the labelled storage range. Propylene glycol is used at 10–20% v/v, glycerol at 10–20% v/v, and sorbitol solution at 20–40% v/v to achieve a clear solution at ambient temperature; ethanol may be included at 5–10% v/v in some regulatory jurisdictions but is avoided in paediatric lines where possible. The pH is buffered between 5.0 and 6.0 with citrate or phosphate buffer at 0.02–0.05 M, because hydrolysis of the acetamido group to 4-aminophenol is fast under strongly acidic or alkaline conditions and is oxygen-dependent. Sodium metabisulfite or washed nitrogen sparging is used to reduce dissolved oxygen during compounding, and the bulk solution is protected from light because photolytic discoloration can occur in clear glass or polyethylene terephthalate bottles. Preservatives such as methyl parahydroxybenzoate at 0.18% w/v and propyl parahydroxybenzoate at 0.02% w/v are included when the product is a multi-dose presentation, with preservative efficacy tested according to Ph. Eur. 5.1.3 or USP Chapter <51>. Viscosity modifiers and sweeteners are selected to avoid interaction with the API; high concentrations of sorbitol can lower the free-water content and reduce hydrolysis, but excessively high viscosity slows mixing and can interfere with filterability during syrup transfer. The finished syrup is filled into amber glass or dark polyethylene terephthalate bottles, and stability is evaluated under ICH Q1A(R2) conditions, with particular attention to 4-aminophenol, clarity, pH, and preservative content over the shelf life.

Terminal Sterilization and Impurity Control in Paracetamol Intravenous Infusion

Injectable paracetamol is manufactured as a sterile solution at 10 mg/mL, usually filled into 100 mL Type I borosilicate glass vials or ready-to-use polyolefin bags, and the major process conflict is the balance between terminal sterilization and the formation of 4-aminophenol during heat exposure. The bulk solution is prepared by dissolving paracetamol in water for injection with an isotonicity modifier, typically mannitol at approximately 3.8–4.0% w/v, because the API contributes limited osmotic pressure at 10 mg/mL. Sodium chloride can be used in alternative formulations, but buffering is required to keep the pH between 5.0 and 6.0, with a target of 5.5 where the heat-induced hydrolysis rate is minimised. A low-concentration antioxidant such as cysteine hydrochloride or N-acetylcysteine is added, and the solution is sparged with nitrogen until headspace oxygen is below 1.0% v/v before terminal sterilization. The filled containers are sterilised by moist heat with an F0 of not less than 15 minutes at 121.1°C according to Ph. Eur. 5.1.1; however, the thermal cycle must be justified by degradation data showing that 4-aminophenol remains within the product-specific limit after sterilization and throughout shelf life. The API monograph Ph. Eur. 0049 controls impurity K as a quality attribute, and the finished injectable dossier applies ICH Q3B thresholds for degradation products because the maximum daily dose exceeds 2 g. Sterile filtration through 0.22 µm filters is performed before filling as an additional microbial reduction step, but filtration is not a substitute for terminal sterilization unless the product-specific degradation profile does not support the thermal cycle. Release testing includes sterility per Ph. Eur. 2.6.1, bacterial endotoxins per USP Chapter <85>, particulate matter per USP Chapter <788> with limits for large-volume parenterals, pH, osmolality, and assay of the active content. The primary packaging is selected for low oxygen permeability and minimal extractables, because aqueous paracetamol can leach trace substances from rubber stoppers and polyolefin films over prolonged contact.

Recovered tablet cores and rejected capsule granules are not routinely blended back into primary paracetamol drug-product batches without validation, because recompacted API crystals undergo work hardening and produce a denser particle population that alters compactibility and can shift dissolution behaviour even when chemical assay remains unchanged. When rework is permitted under the regulatory filing, the ratio of reworked material to fresh granulate is typically capped at 10–20% w/w, and the reworked stream is milled through the same screen as the primary granulate before blending. The process risk is greatest for direct-compression tablet lines because the coarse–fine balance that controls powder flow and tablet hardness is disturbed by the addition of brittle, previously compressed API granules. In roller-compacted systems, rework density is measured by bulk and tapped density, and the Carr index is maintained below 25% to ensure acceptable die filling on high-speed rotary presses. Analytical release for reworked batches includes particle-size distribution, dissolution, and blend uniformity, not merely assay, because the physical state of the API can lag behind the chemical potency. For oral suspension and effervescent dosage forms, rework is generally avoided when moisture-sensitive or suspending-agent components have been exposed to open conditions, since partial hydration or pre-reaction cannot be reversed by drying without creating additional degradation products or altered dispersion behaviour. In injectable manufacturing, rework of a sterilised or partially filled solution is not performed; the batch is rejected if any critical in-process control exceeds the validated window, because the terminal sterilization and oxygen-control strategy cannot be repeated reliably without exceeding the permitted impurity profile.